Immunotherapy is a broad category of cancer therapies that triggers the body's immune system to fight cancer cells. Immunotherapy drugs help boost the immune system and help the body find and destroy cancer cells. These drugs can be used to treat many different types of cancer. Immunotherapy can be used alone or in combination with chemotherapy and/or other cancer treatments. Although originally developed as a treatment against cancer, immunotherapy drugs are gradually being used to treat other diseases as well. Immunotherapy drugs are being used to treat a wide array of cancers including melanoma, lymphoma, non-small cell lung cancer, kidney cancer, bladder cancer, and some head and neck cancers. Therefore, with the increasing prevalence of cancer, the demand for immunotherapy drugs is also increasing.
Market Statistics:
The global immunotherapy drugs market was valued at US$ 188.9 Bn in 2021 and is forecast to reach a value of US$ 405.7 Bn by 2028 at a CAGR of 11.5% between 2022 and 2028.
North America held dominant position in the global immunotherapy drugs market in 2021, accounting for 56.3% share in terms of volume, followed by Europe and Asia Pacific, respectively.
Figure 1. Global Immunotherapy Drugs Market Share (%), by Region, 2021
Recent Developments:
In March 2022, Nextera AS strategically collaborated with Zelluna Immunotherapy AS for the development of optimized TCRs for cancer immunotherapy.
In February 2022, Biomunex Pharmaceuticals collaborated with Institut Curie to develop an immunotherapy drug candidate to treat hematological malignancies using Biomunex’ BiXAR technology.
In January 2021, Boehringer Ingelheim International GmbH signed a licensing agreement with Enara Bio for novel cancer immunotherapies by utilizing Enara Bio’s Dark Antigen discovery platform.
Immunotherapy Drugs Market Report Coverage
| Report Coverage |
Details |
| Base Year: |
2021 |
Market Size in 2021: |
US$ 188.9 Bn |
| Historical Data for: |
2017 to 2020 |
Forecast Period: |
2022 to 2028 |
| Forecast Period 2022 to 2028 CAGR: |
11.5% |
2028 Value Projection: |
US$ 405.7 Bn |
| Geographies covered: |
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
|
| Segments covered: |
- By Product: Monoclonal Antibodies, Immuno-Modulators, Car T-Cell Therapy, Others
- By Applications: Cancer, Autoimmune & Inflammatory Diseases, Others
|
| Companies covered: |
F. Hoffmann-La Roche AG, Merck Group, Bristol Myers Squibb, GlaxoSmithKline, AstraZeneca, Novartis, Janssen Pharmaceuticals, among others.
|
| Growth Drivers: |
- Increasing prevalence of cancer
- Increasing demand for immunotherapy drugs
|
| Restraints & Challenges: |
- High cost of immunotherapy treatment
- Side effects of immunotherapy drugs
|
Market Drivers:
- Increasing prevalence of chronic diseases, such as cancer, worldwide is expected to augment growth of the global immunotherapy drugs market during the forecast period. Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. Immunotherapy drugs help prevent, control, and eliminate cancer (help fight cancer). For instance, according to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases will be diagnosed in the United States and 609,360 people will die from the disease. Thus, with the increasing prevalence of cancer, the demand for immunotherapy drugs is also increasing.
- Increasing demand for immunotherapy drugs is expected to boost the growth of the global immunotherapy drugs market over the forecast period. There is an increasing demand for safe and effective immunotherapy drugs worldwide due to increasing prevalence of chronic diseases and increasing awareness among people about cancer treatment. In March 2022, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer. The FDA approved relatlimab for use in combination with Bristol's immunotherapy Opdivo as an initial treatment for advanced melanoma.
Figure 2. Global Immunotherapy Drugs Market Share (%), by Product, 2021
Market Restraints:
- High cost of immunotherapy treatment (cancer treatment) is expected to hamper the growth of the global immunotherapy drugs market. For instance, immunotherapies in particular often cost more than $100,000 per patient. Doctors now use immunotherapies in combination, which means those costs can quickly double or triple. Pharma companies justify high immunotherapy cost by highlighting the value of these immunotherapy drugs and the continual investment of their profits into R&D to discover new cancer drugs.
- Side-effects of immunotherapy drugs are expected to hinder growth of the immunotherapy drugs market. People might be on immunotherapy for a long time, and side effects can occur at any point during and after treatment. A study of over a thousand cancer patients treated with immunotherapy drugs has found these patients are at higher risk of heart problems, including death from a heart attack or stroke. Moreover, immunotherapy can take a toll on your body and be both physically and mentally exhausting.
Market Opportunities:
- High adoption of immunotherapy drugs over conventional treatments is expected to provide significant growth opportunities for players active in the global immunotherapy drugs market. For instance, immunotherapy has revolutionized cancer therapies that have begun to shift the curve of cancer patients by increasing their lifespan. Cancer immunotherapy can work on many different types of cancer, and thus, there is an increase in demand for immunotherapy drugs. In April 2021, the U.S. FDA approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, esophageal adenocarcinoma, and gastroesophageal junction cancer.
- Increasing demand for monoclonal antibodies and biosimilars is expected to offer lucrative growth opportunities for players in the global immunotherapy drugs market. A biosimilar is a version of a known and proven biologic drug. There are many biologic drugs (immunotherapy drugs) now being used to treat cancer, and some biosimilars have been approved to treat cancer. For instance, in May 2022, Biocon Biologics and Viatris (Mylan) launched bevacizumab under the brand name Abevmy in Canada. It is a biosimilar to Roche’s Avastin and has been approved by Health Canada across four oncology indications.
Market Trends/Key Takeaways:
- Rise in prevalence of autoimmune diseases is expected to propel the growth of the global immunotherapy drugs market. For instance, autoimmune diseases are a family of more than 80 chronic and life-threatening illnesses. According to the National Institutes of Health, over 23.5 million people in the U.S. suffer from an autoimmune disease, and the prevalence is rising.
- Frequent approvals of novel drugs is expected to drive growth of the global immunotherapy drugs market. For instance, in October 2021, the FDA approved Tecentriq (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1≥1%, as determined by an FDA-approved test.
Competitive Landscape:
- Hoffmann-La Roche AG
- Merck Group
- Bristol Myers Squibb
- GlaxoSmithKline
- AstraZeneca
- Novartis
- Janssen Pharmaceuticals
Immunotherapy is a cancer treatment that enhances the immune system's ability to fight cancer. Immunotherapy is preferable than the old technique as it helps treat a wider range of cancer, provide long-term cancer protection, and has less side effects. Immunotherapy drugs are used to treat different types of cancers. They work by activating the immune system to mobilize the target, directing the immune system toward cancer-specific targets, and triggering a response capable of destroying cancer cells. Immunotherapy drugs enable immune system to recognize and target cancer cells, making it a universal answer to cancer, and thus, there is an increasing demand for immunotherapy drugs worldwide.
Market Dynamics:
High prevalence of cancer, increasing adoption of immunotherapy drugs, rise in demand for monoclonal antibodies and biosimilars, and frequent approvals of novel drugs are some major factors expected to drive growth of the global immunotherapy drugs market during the forecast period. For instance, immunotherapy is a class of cancer treatments that trigger the immune system to fight cancer cells, and thus, has led to an increase in the use of immunotherapy or immunotherapy drugs around the world.
In March 2022, the U.S. Food and Drug Administration (FDA) approved a novel therapy for patients with metastatic or inoperable melanoma, an aggressive type of skin cancer. Moreover, in May 2022, FDA expanded its approval for a personalized cellular therapy developed at the University of Pennsylvania’s (Penn’s) Abramson Cancer Center, this time for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. It remains the only CAR-T cell therapy approved for both adult and pediatric patients.
Key features of the study:
- This report provides in-depth analysis of the global immunotherapy drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global immunotherapy drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Merck Group, Bristol Myers Squibb, GlaxoSmithKline, AstraZeneca, Novartis, and Janssen Pharmaceuticals, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global immunotherapy drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immunotherapy drugs market.
Detailed Segmentation:
- Global Immunotherapy Drugs Market By Product:
-
- Monoclonal Antibodies
- Immuno Modulators
- Car T-Cell Therapy
- Others
- Global Immunotherapy Drugs Market By Applications:
- Cancer
- Autoimmune & Inflammatory Diseases
- Others
- Global Immunotherapy Drugs Market By Geography:
- Europe
- APAC
- North America
- Latin America
- Middle East & Africa
